Recent advances in leishmaniasis treatment

International Journal of Infectious Diseases

Volumn 15, Issue 8, 2011, Pages

  Tiuman, Tatiana S ^a   Santos, Adriana O ^a   Ueda Nakamura, Tânia ^a   Filho, Benedito P Dias ^a   Nakamura, Celso V ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Chemotherapeutics; Drug delivery systems; Leishmaniasis treatment

Indexed keywords

2 [(2,4 DICHLORO 5 METHYLPHENYL)SULFANYL] 1,3 DINITRO 5 (TRIFLUOROMETHYL BENZENE); 4 BUTOXYPHENYL) N' [2 [(7 CHLOROQUINOLIN 4 YL)AM INO]ETHYL]UREA; AMIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANNONA CORIACEA EXTRACT; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; BACCHARIS DRACUNCULIFOLIA EXTRACT; DYSOXYLUM BINECTARIFERUM EXTRACT; EDELFOSINE; FERULA SZOWITSIANA EXTRACT; GOUANIA LUPULOIDES EXTRACT; ILMOFOSINE; LIPID TRANSFER PROTEIN; LIPOSOME; MEGLUMINE ANTIMONATE; MILTEFOSINE; NANOPARTICLE; PAGIANTHA CERIFERA EXTRACT; PAROMOMYCIN; PENTAMIDINE; PERIFOSINE; PLANT EXTRACT; PYRIMIDINE DERIVATIVE; SCROPHULARIA CRYPTOPHILA EXTRACT; SITAMAQUINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; LEISHMANIASIS; MEDICINAL PLANT; NEPHROTOXICITY; NONHUMAN; REVIEW; SKIN LEISHMANIASIS; TERATOGENICITY; VISCERAL LEISHMANIASIS;

DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; TRYPANOCIDAL AGENTS;

EID: 79961029192     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.03.021     Document Type: Review

References (119)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27:305-318.
2. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
3. Reithinger R., Dujardin J.C., Louzir H., Pirmez C., Alexander B., Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007, 7:581-596.
4. Boelaert M., Criel B., Leeuwenburg J., Van Damme W., Le Ray D., Van der Stuyft P. Visceral leishmaniasis control: a public health perspective. Trans R Soc Trop Med Hyg 2000, 94:465-471.
5. Kamhawi S. Phlebotomine sand flies and Leishmania parasites: friends or foes?. Trends Parasitol 2006, 22:439-445.
6. Burchmore R.J., Barrett M.P. Life in vacuoles-nutrient acquisition by Leishmania amastigotes. Int J Parasitol 2001, 31:1311-1320.
7. Hepburn N.C. Cutaneous leishmaniasis. Clin Exp Dermatol 2000, 25:363-370.
8. World Health Organization. Visceral leishmaniasis therapy: statement on the outcome of a meeting. Geneva: WHO; 2009. Available at: (accessed August 16, 2010). http://www.who.int/leishmaniasis/resources/Leish_VL_Therapy_statement.pdf.
9. Maltezou H.C. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010, 2010:617521.
10. World Health Organization. Leishmaniasis: magnitude of the problem. Geneva: WHO; 2009. Available at: (accessed November 30, 2010). http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html.
11. Shaw J. The leishmaniases-survival and expansion in a changing world. Mem Inst Oswaldo Cruz 2007, 102:541-547.
12. Fernández-Guerrero M.L., Robles P., Rivas P., Mójer F., Muñíz G., Górgolas M. Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 2004, 90:11-16.
13. Carnaúba D., Konishi C.T., Petri V., Martinez I.C.P., Shimizu L., Pereira-Chioccola V.L. Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: a case report. Int J Infect Dis 2009, 13:504-507.
14. Croft S.L., Barret M.P., Urbina J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005, 21:508-512.
15. Natera S., Machuca C., Padrón-Nieves M., Romero A., Díaz E., Ponte-Sucre A. Leishmania spp: profi{ligature}ciency of drug-resistant parasites. Int J Antimicrob Agents 2007, 29:637-642.
16. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19:111-126.
17. Herwaldt B.L. Leishmaniasis. Lancet 1999, 2:1191-1199.
18. Carrión J., Folgueira C., Alonso C. Development of immunization strategies against leishmaniosis based on the Leishmania histones pathoantigens. Procedia Vaccinol 2009, 1:101-103.
19. Amato V.S., Tuon F.F., Bacha H.A., Neto V.A., Nicodemo A.C. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 2008, 105:1-9.
20. Arevalo J., Ramirez L., Adaui V., Zimic M., Tulliano G., Miranda-Verástegui C., et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007, 195:1846-1851.
21. Centers for Disease Control and Prevention (CDC). Parasites-leishmaniasis. Resources for health professionals. Atlanta, GA: CDC; 2010. Available at: (accessed December 2, 2010). http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html.
22. Ouellette M., Drummelsmith J., Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 2004, 7:257-266.
23. Croft S.L., Coombs G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003, 19:502-508.
24. Yardley V., Croft S.L. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000, 13:243-248.
25. Ordóñez-Gutiérrez L., Espada-Fernández R., Dea-Ayuela M.A., Torrado J.J., Bolás-Fernandez F., Alunda J.M. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 2007, 30:325-329.
26. Sindermann H., Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006, 100:17-20.
27. Croft S.L., Engel J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006, 100:4-8.
28. Berman J., Bryceson A.D., Croft S., Engel J., Gutteridge W., Karbwang J., et al. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 2006, 100:41-44.
29. Pérez-Victoria F.J., Sánchez-Cañete M.P., Seifert K., Croft S.L., Sundar S., Castanys S., et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat 2006, 9:26-39.
30. Sundar S., Murray H.W. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005, 83:394-395.
31. Sundar S., Olliaro P.L. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007, 3:733-740.
32. Santa-Rita R.M., Henriques-Pons A., Barbosa H.S., Castro S.L. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004, 54:704-710.
33. Cabrera-Serra M.G., Lorenzo-Morales J., Romero M., Valladares B., Pinero J.E. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res 2007, 100:1155-1157.
34. Cabrera-Serra M.G., Valladares B., Piñero J.E. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop 2008, 108:20-25.
35. Wasunna M.K., Rashid J.R., Mbui L., Kirigi G., Kinoti D., Lodenyo H., et al. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005, 73:871-876.
36. Croft S.L., Yardley V., Kendrick H. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 2002, 96:127-129.
37. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007, 356:2571-2581.
38. Ben Salah A., Zakraoui H., Zaatour A., Ftaiti A., Zaafouri B., Garraoui A., et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995, 53:162-166.
39. Armijos R.X., Weigel M.M., Calvopiña M., Mancheno M., Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004, 91:153-160.
40. Gonçalves G.S., Fernandes A.P., Souza R.C., Cardoso J.E., Oliveira-Silva F., Maciel F.C., et al. Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 2005, 93:161-167.
41. Iwu M.M., Jackson J.E., Schuster B.G. Medicinal plants in the fight against leishmaniasis. Parasitol Today 1994, 10:65-68.
42. Rocha L.G., Almeida J.R., Macêdo R.O., Barbosa-Filho J.M. A review of natural products with antileishmanial activity. Phytomedicine 2005, 12:514-535.
43. Wang J., Peng Q., Li G. New compounds of natural resources in 2008. Afr J Biotechnol 2009, 8:4299-4307.
44. Rates S.M. Plants as source of drugs. Toxicon 2001, 39:603-613.
45. Eloff J.N. Which extractant should be used for the screening and isolation of antimicrobial components from plants?. J Ethnopharmacol 1998, 60:1-8.
46. Beutler J.A. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol 2009, 46. 9.11.1.
47. Sereno D., Cordeiro da Silva A., Mathieu-Daude F., Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 2007, 56:3-7.
48. Hodgkinson V.H., Soong L., Duboise S.M., McMahon-Pratt D. Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms. Exp Parasitol 1996, 83:94-105.
49. Croft S.L., Seifert K., Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006, 123:399-410.
50. Callahan H.L., Portal A.C., Devereaux R., Grogl M. An axenic amastigote system for drug screening. Antimicrob Agents Chemother 1997, 41:818-822.
51. Mikus J., Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 2000, 48:265-269.
52. Ganguly S., Bandyopadhyay S., Sarkar A., Chatterjee M. Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. J Microbiol Methods 2006, 66:79-86.
53. Chan M.M., Bulinski J.C., Chang K.P., Fong D. A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein. Parasitol Res 2003, 89:266-271.
54. Monte-Alegre A., Ouaissi A., Sereno D. Leishmania amastigotes as targets for drug screening. Kinetoplastid Biol Dis 2006, 23:5-6.
55. Mandal S., Maharjan M., Ganguly S., Chatterjee M., Singh S., Buckner F.S., et al. High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay. Indian J Exp Biol 2009, 47:475-479.
56. Kigondu E.V., Rukunga G.M., Keriko J.M., Tonui W.K., Gathirwa J.W., Kirira P.G., et al. Anti-parasitic activity and cytotoxicity of selected medicinal plants from Kenya. J Ethnopharmacol 2009, 25:504-509.
57. Tempone A.G., Borborema S.E., de Andrade H.F., de Amorim Gualda N.C., Yogi A., Carvalho C.S., et al. Antiprotozoal activity of Brazilian plant extracts from isoquinoline alkaloid-producing families. Phytomedicine 2005, 12:382-390.
58. Osorio E., Arango G.J., Jiménez N., Alzate F., Ruiz G., Gutiérrez D., et al. Antiprotozoal and cytotoxic activities in vitro of Colombian Annonaceae. J Ethnopharmacol 2007, 22:630-635.
59. Lamidi M., DiGiorgio C., Delmas F., Favel A., Eyele Mve-Mba C., Rondi M.L., et al. In vitro cytotoxic, antileishmanial and antifungal activities of ethnopharmacologically selected Gabonese plants. J Ethnopharmacol 2005, 14:185-190.
60. Castillo D., Arevalo J., Herrera F., Ruiz C., Rojas R., Rengifo E., et al. Spirolactone iridoids might be responsible for the antileishmanial activity of a Peruvian traditional remedy made with Himatanthus sucuuba (Apocynaceae). J Ethnopharmacol 2007, 13:410-414.
61. Billo M., Fournet A., Cabalion P., Waikedre J., Bories C., Loiseau P., et al. Screening of New Caledonian and Vanuatu medicinal plants for antiprotozoal activity. J Ethnopharmacol 2005, 15:569-575.
62. Santos A.O., Santin A.C., Yamaguchi M.U., Cortez L.E., Ueda-Nakamura T., Dias-Filho B.P., et al. Antileishmanial activity of an essential oil from the leaves and flowers of Achillea millefolium. Ann Trop Med Parasitol 2010, 104:475-483.
63. Karioti A., Skaltsa H., Kaiser M., Tasdemir D. Trypanocidal, leishmanicidal and cytotoxic effects of anthecotulide-type linear sesquiterpene lactones from Anthemis auriculata. Phytomedicine 2009, 16:783-787.
64. Silva Filho A.A., Resende D.O., Fukui M.J., Santos F.F., Pauletti P.M., Cunha W.R., et al. In vitro antileishmanial, antiplasmodial and cytotoxic activities of phenolics and triterpenoids from Baccharis dracunculifolia D. C. (Asteraceae). Fitoterapia 2009, 80:478-482.
65. Valadeau C., Pabon A., Deharo E., Albán-Castillo J., Estevez Y., Lores F.A., et al. Medicinal plants from the Yanesha (Peru): evaluation of the leishmanicidal and antimalarial activity of selected extracts. J Ethnopharmacol 2009, 123:413-422.
66. Gachet M.S., Lecaro J.S., Kaiser M., Brun R., Navarrete H., Muñoz R.A., et al. Assessment of anti-protozoal activity of plants traditionally used in Ecuador in the treatment of leishmaniasis. J Ethnopharmacol 2010, 2:184-197.
67. Tiuman T.S., Ueda-Nakamura T., Dias Filho B.P., Cortez D.A., Nakamura C.V. Studies on the effectiveness of Tanacetum parthenium against Leishmania amazonensis. Acta Protozool 2005, 44:245-251.
68. Tiuman T.S., Ueda-Nakamura T., Cortez D.A., Dias Filho B.P., Morgado-Díaz J.A., Souza W., et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005, 49:176-182.
69. Silva B.P., Cortez D.A., Violin T.Y., Dias Filho B.P., Nakamura C.V., Ueda-Nakamura T., et al. Antileishmanial activity of a guaianolide from Tanacetum parthenium (L.) Schultz Bip. Parasitol Int 2010, 59:643-646.
70. Braga F.G., Bouzada M.L., Fabri R.L., de O., Matos M., Moreira F.O., Scio E., et al. Antileishmanial and antifungal activity of plants used in traditional medicine in Brazil. J Ethnopharmacol 2007, 4:396-402.
71. Brenzan M.A., Nakamura C.V., Dias Filho B.P., Ueda-Nakamura T., Young M.C., Cortez D.A. Antileishmanial activity of crude extract and coumarin from Calophyllum brasiliense leaves against Leishmania amazonensis. Parasitol Res 2007, 101:715-722.
72. Muzitano M.F., Tinoco L.W., Guette C., Kaiser C.R., Rossi-Bergmann B., Costa S.S. The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry 2006, 67:2071-2077.
73. Santos A.O., Ueda-Nakamura T., Dias-Filho B.P., Veiga-Junior V.F., Pinto A.C., Nakamura C.V. Effect of Brazilian copaiba oils on Leishmania amazonensis. J Ethnopharmacol 2008, 120:204-208.
74. Jullian V., Bonduelle C., Valentin A., Acebey L., Duigou A.G., Prévost M.F., et al. New clerodane diterpenoids from Laetia procera (Poepp.) Eichler (Flacourtiaceae), with antiplasmodial and antileishmanial activities. Bioorg Med Chem Lett 2005, 15:5065-5070.
75. Weniger B., Vonthron-Sénécheau C., Kaiser M., Brun R., Anton R. Comparative antiplasmodial, leishmanicidal and antitrypanosomal activities of several biflavonoids. Phytomedicine 2006, 13:176-180.
76. Desrivot J., Waikedre J., Cabalion P., Herrenknecht C., Bories C., Hocquemiller R., et al. Antiparasitic activity of some New Caledonian medicinal plants. J Ethnopharmacol 2007, 30:7-12.
77. Ueda-Nakamura T., Mendonça-Filho R.R., Morgado-Díaz J.A., Maza P.K., Dias-Filho B.P., Cortez D.A., et al. Antileishmanial activity of eugenol-rich essential oil from Ocimum gratissimum. Parasitol Int 2006, 55:99-105.
78. Mandal D., Panda N., Kumar S., Banerjee S., Mandal N.B., Sahu N.P. A triterpenoid saponin possessing antileishmanial activity from the leaves of Careya arborea. Phytochemistry 2006, 67:183-190.
79. Danelli M.G., Soares D.C., Abreu H.S., Peçanha L.M., Saraiva E.M. Leishmanicidal effect of LLD-3 (1), a nor-triterpene isolated from Lophanthera lactescens. Phytochemistry 2009, 70:608-614.
80. Lakshmi V., Pandey K., Kapil A., Singh N., Samant M., Dube A. In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani. Phytomedicine 2007, 14:36-42.
81. Monzote L., García M., Montalvo A.M., Scull R., Miranda M. Chemistry, cytotoxicity and antileishmanial activity of the essential oil from Piper auritum. Mem Inst Oswaldo Cruz 2010, 105:168-173.
82. Estevez Y., Castillo D., Pisango M.T., Arevalo J., Rojas R., Alban J., et al. Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group. J Ethnopharmacol 2007, 1:254-259.
83. Vendrametto M.C., Santos A.O., Nakamura C.V., Dias-Filho B.P., Cortez D.A., Ueda-Nakamura T. Evaluation of antileishmanial activity of eupomatenoid-5, a compound isolated from leaves of Piper regnellii var. pallescens. Parasitol Int 2010, 59:154-158.
84. Santin M.R., Santos A.O., Nakamura C.V., Dias-Filho B.P., Ferreira I.C., Ueda-Nakamura T. In vitro activity of the essential oil of Cymbopogon citratus and its major component (citral) on Leishmania amazonensis. Parasitol Res 2009, 105:1489-1496.
85. Arango V., Robledo S., Séon-Méniel B., Figadère B., Cardona W., Sáez J., et al. Coumarins from Galipea panamensis and their activity against Leishmania panamensis. J Nat Prod 2010, 28:1012-1014.
86. Tasdemir D., Brun R., Franzblau S.G., Sezgin Y., Calis I. Evaluation of antiprotozoal and antimycobacterial activities of the resin glycosides and the other metabolites of Scrophularia cryptophila. Phytomedicine 2008, 15:209-215.
87. Iranshahi M., Arfa P., Ramezani M., Jaafari M.R., Sadeghian H., Bassarello C., et al. Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes. Phytochemistry 2007, 68:554-561.
88. Brenzan M.A., Nakamura C.V., Dias Filho B.P., Ueda-Nakamura T., Young M.C., Côrrea A.G., et al. Structure-activity relationship of (-) mammea A/BB derivatives against Leishmania amazonensis. Biomed Pharmacother 2008, 62:651-658.
89. Delfín D.A., Morgan R.E., Zhu X., Werbovetz K.A. Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies. Bioorg Med Chem 2009, 17:820-829.
90. Al-Qahtani A., Siddiqui Y.M., Bekhit A.A., El-Sayed O.A., Aboul-Enein H.Y., Al-Ahdal M.N. Inhibition of growth of Leishmania donovani promastigotes by newly synthesized 1,3,4-thiadiazole analogs. Saudi Pharm J 2009, 16:227-232.
91. Sunduru N., Nishi, Palne S., Chauhan P.M., Gupta S. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. Eur J Med Chem 2009, 44:2473-2481.
92. Barbosa T.P., Junior C.G., Silva F.P., Lopes H.M., Figueiredo L.R., Sousa S.C., et al. Improved synthesis of seven aromatic Baylis-Hillman adducts (BHA): evaluation against Artemia salina Leach. and Leishmania chagasi. Eur J Med Chem 2009, 44:1726-1730.
93. Musonda C.C., Whitlock G.A., Witty M.J., Brun R., Kaiser M. Synthesis and evaluation of 2-pyridyl pyrimidines with in vitro antiplasmodial and antileishmanial activity. Bioorg Med Chem Lett 2009, 19:401-405.
94. Poorrajab F., Ardestani S.K., Emami S., Behrouzi-Fardmoghadam M., Shafiee A., Foroumadi A. Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation. Eur J Med Chem 2009, 44:1758-1762.
95. Srinivas N., Palne S., Nishi, Gupta S., Bhandari K. Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents. Bioorg Med Chem Lett 2009, 15:324-327.
96. Tonin L.T., Panice M.R., Nakamura C.V., Rocha K.J., Santos A.O., Ueda-Nakamura T., et al. Antitrypanosomal and antileishmanial activities of novel N-alkyl-(1-phenylsubstituted-beta-carboline)-3-carboxamides. Biomed Pharmacother 2010, 64:386-389.
97. Aponte J.C., Vaisberg A.J., Castillo D., Gonzalez G., Estevez Y., Arevalo J., et al. Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem 2010, 18:2880-2886.
98. Graebin C.S., Madeira M.F., Yokoyama-Yasunaka J.K., Miguel D.C., Uliana S.R., Benitez D., et al. Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma. Eur J Med Chem 2010, 45:1524-1528.
99. Nava-Zuazo C., Estrada-Soto S., Guerrero-Álvarez J., León-Rivera I., Molina-Salinas G.M., Said-Fernández S., et al. Design, synthesis, and in vitro antiprotozoal, antimycobacterial activities of N-{2-[(7-chloroquinolin-4-yl)amino]ethyl}ureas. Bioorg Med Chem 2010, 18:6398-6403.
100. Arruebo M., Fernández-Pacheco R., Ibarra M.R., Santamaría J. Magnetic nanoparticles for drug delivery. Nanotoday 2007, 2:22-32.
101. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
102. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007, 59:631-644.
103. Chellat F., Merhi Y., Moreau A., Yahia L.H. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005, 26:7260-7275.
104. Date A.A., Joshi M.S., Patravale V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007, 59:505-521.
105. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19.
106. Kayser O., Olbrich C., Yardley V., Kiderlen A.F., Croft S.L. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003, 254:73-75.
107. Santangelo R., Paderu P., Delmas G., Chen Z., Mannino R., Zarif L., et al. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000, 44:2356-2360.
108. Mendoza A.E., Rayo M., Mollinedo F., Blanco-Prieto M.J. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur J Pharm Biopharm 2008, 68:207-213.
109. Carvalho A.O., Gomes V.M. Role of plant lipid transfer proteins in plant cell physiology-a concise review. Peptides 2007, 28:1144-1153.
110. Jégou S., Douliez J., Mollé D., Boivin P., Marion D. Purification and structural characterization of LTP1 polypeptides from beer. J Agric Food Chem 2000, 48:5023-5029.
111. Cheng H.C., Cheng P.T., Peng P., Lyu P.C., Sun Y.J. Lipid binding in rice nonspecific lipid transfer protein-1 complexes from Oryza sativa. Protein Sci 2004, 13:2304-2315.
112. Tomassen M.M., Barrett D.M., Van Der Valk H.C., Woltering E.J. Isolation and characterization of a tomato non-specific lipid transfer protein involved in polygalacturonase-mediated pectin degradation. J Exp Bot 2007, 58:1151-1160.
113. Ooi L.S., Wong E.Y., Sun S.S., Ooi V.E. Purification and characterization of non-specific lipid transfer proteins from the leaves of Pandanus amaryllifolius (Pandanaceae). Peptides 2006, 27:626-632.
114. Zaman U., Abbasi A. Isolation, purification and characterization of a nonspecific lipid transfer protein from Cuminum cyminum. Phytochemistry 2009, 70:979-987.
115. Pato C., Borgne M.L., Baut G.L., Pape P.L., Marion D., Douliez J. Potential application of plant lipid transfer proteins for drug delivery. Biochem Pharmacol 2001, 62:555-560.
116. Ben Salah A., Buffet P.A., Morizot G., Ben Massoud N., Zâatour A., Ben Alaya N., et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009, 3:e432.
117. Tallarida R.J. The interaction index: a measure of drug synergism. Pain 2002, 98:163-168.
118. Monzote L., Montalvo A.M., Scull R., Miranda M., Abreu J. Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis. Rev Inst Med Trop Sao Paulo 2007, 49:257-260.
119. Wagner H., Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009, 16:97-110.